Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines

被引：19

作者：

Kollaritsch, H ^{[1
]}

Furer, E ^{[1
]}

Herzog, C ^{[1
]}

Wiedermann, G ^{[1
]}

Que, JU ^{[1
]}

Cryz, SJ ^{[1
]}

机构：

[1] SWISS SERUM & VACCINE INST, CH-3001 BERN, SWITZERLAND

来源：

INFECTION AND IMMUNITY | 1996年 / 64卷 / 04期

关键词：

D O I：

10.1128/IAI.64.4.1454-1457.1996

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Healthy adults (n = 330) were randomized to receive either a bivalent vaccine composed of Vibrio cholerae CVD 103-HgR and Salmonella typhi Ty21a or a placebo. The combined vaccine was well tolerated. Approximately 80% of vaccinees manifested a significant rise in anti-S. typhi immunoglobulin G or immunoglobulin A lipopolysaccharide antibody levels. Significant (fourfold or greater) rises in anti-Inab,a or anti-Ogawa vibrio-cidal antibody titer were achieved by 91 and 80% of vaccine recipients, respectively. Elevated baseline vibrio-cidal antibody titers showed a modest suppressive effect on the rate of seroconversion.

引用

页码：1454 / 1457

页数：4

共 30 条

[1]

AMBROSCH F, 1985, MUNCHEN MED WOCHEN, V127, P775

[2] ORAL CHOLERA VACCINE WELL TOLERATED [J].

BARRETT, P ;

CLARKE, P ;

CRYZ, S .

BRITISH MEDICAL JOURNAL, 1993, 307 (6916) :1425-1425

[3] FIELD TRIAL OF ORAL CHOLERA VACCINES IN BANGLADESH - SERUM VIBRIOCIDAL AND ANTITOXIC ANTIBODIES AS MARKERS OF THE RISK OF CHOLERA [J].

CLEMENS, JD ;

VANLOON, F ;

SACK, DA ;

CHAKRABORTY, J ;

RAO, MR ;

AHMED, F ;

HARRIS, JR ;

KHAN, MR ;

YUNUS, M ;

HUDA, S ;

KAY, BA ;

SVENNERHOLM, AM ;

HOLMGREN, J .

JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (06) :1235-1242

[4] MAGNITUDE, KINETICS, AND DURATION OF VIBRIOCIDAL ANTIBODY-RESPONSES IN NORTH AMERICANS AFTER INGESTION OF VIBRIO-CHOLERAE [J].

CLEMENTS, ML ;

LEVINE, MM ;

YOUNG, CR ;

BLACK, RE ;

LIM, YL ;

ROBINSBROWNE, RM ;

CRAIG, JP .

JOURNAL OF INFECTIOUS DISEASES, 1982, 145 (04) :465-473

[5] RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF THE LIVE ORAL CHOLERA VACCINE STRAIN CVD-103-HGR IN SWISS ADULTS [J].

CRYZ, SJ ;

LEVINE, MM ;

KAPER, JB ;

FURER, E ;

ALTHAUS, B .

VACCINE, 1990, 8 (06) :577-580

[6] POSTMARKETING EXPERIENCE WITH LIVE ORAL TY21A VACCINE [J].

CRYZ, SJ .

LANCET, 1993, 341 (8836) :49-50

[7] SAFETY AND IMMUNOGENICITY OF SALMONELLA-TYPHI TY21A VACCINE IN YOUNG THAI CHILDREN [J].

CRYZ, SJ ;

VANPRAPAR, N ;

THISYAKORN, U ;

OLANRATMANEE, T ;

LOSONSKY, G ;

LEVINE, MM ;

CHEARSKUL, S .

INFECTION AND IMMUNITY, 1993, 61 (03) :1149-1151

[8] SAFETY AND IMMUNOGENICITY OF A BOOSTER DOSE OF VIBRIO-CHOLERAE CVD-103-HGR LIVE ORAL CHOLERA VACCINE IN SWISS ADULTS [J].

CRYZ, SJ ;

LEVINE, MM ;

LOSONSKY, G ;

KAPER, JB ;

ALTHAUS, B .

INFECTION AND IMMUNITY, 1992, 60 (09) :3916-3917

[9] SAFETY AND IMMUNOGENICITY OF A LIVE ORAL BIVALENT TYPHOID-FEVER (SALMONELLA-TYPHI TY21A) CHOLERA (VIBRIO-CHOLERAE CVD 103-HGR) VACCINE IN HEALTHY-ADULTS [J].

CRYZ, SJ ;

QUE, JU ;

LEVINE, MM ;

WIEDERMANN, G ;

KOLLARITSCH, H .

INFECTION AND IMMUNITY, 1995, 63 (04) :1336-1339

[10] SEROEPIDEMIOLOGICAL STUDIES OF EL-TOR CHOLERA IN BANGLADESH - ASSOCIATION OF SERUM ANTIBODY-LEVELS WITH PROTECTION [J].

GLASS, RI ;

SVENNERHOLM, AM ;

KHAN, MR ;

HUDA, S ;

HUQ, MI ;

HOLMGREN, J .

JOURNAL OF INFECTIOUS DISEASES, 1985, 151 (02) :236-242

← 1 2 3 →